1444-P: Trends and Disparities in Continuous Glucose Monitoring Use in U.S. Youth and Adults with Type 1 Diabetes—2008–2022

IF 6.2 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2024-06-21 DOI:10.2337/db24-1444-p

MICHAEL FANG, YUNWEN XU, JOSEF CORESH, SHOSHANA BALLEW, ELIZABETH SELVIN, JUNG-IM SHIN

{"title":"1444-P: Trends and Disparities in Continuous Glucose Monitoring Use in U.S. Youth and Adults with Type 1 Diabetes—2008–2022","authors":"MICHAEL FANG, YUNWEN XU, JOSEF CORESH, SHOSHANA BALLEW, ELIZABETH SELVIN, JUNG-IM SHIN","doi":"10.2337/db24-1444-p","DOIUrl":null,"url":null,"abstract":"Introduction: Continuous glucose monitoring (CGM) technology has revolutionized the management of type 1 diabetes. However, trends and disparities in CGM use remain poorly characterized in general type 1 diabetes population. Methods: We conducted a serial cross-sectional analysis of youth and adults with type 1 diabetes using de-identified electronic health record data from the Optum Labs Data Warehouse. Type 1 diabetes status was determined using a validated algorithm. Use of CGM was ascertained by National Drug Codes from prescription order data. We examined trends in CGM use from 2008-2010 to 2020-2022, overall and by age, sex, race/ethnicity, and insurance type. Results: We included 128,821 individuals with type 1 diabetes (17% under age 18 years; 48% female; 78% non-Hispanic White). From 2008-2010 to 2020-2022, the use of CGM increased from &lt;1% to 47% in youth and 2% to 37% in adults with type 1 diabetes (Fig A1 and A2). Uptake of CGM was similar across age and sex, but substantially lower in racial/ethnic minority patients and those with Medicaid insurance (Fig B1-E2). Conclusion: Over the past 15 years, the use of CGM has grown significantly among persons with type 1 diabetes in the US. However, racial/ethnic and socioeconomic disparities have widened in both youth and adults. There is an urgent need to expand access to care and diabetes technology to improve care in this population. Disclosure M. Fang: None. Y. Xu: None. J. Coresh: Consultant; SomaLogic, Healthy.io. S. Ballew: None. E. Selvin: None. J. Shin: None. Funding K01 DK138273-01","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":null,"pages":null},"PeriodicalIF":6.2000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-1444-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Continuous glucose monitoring (CGM) technology has revolutionized the management of type 1 diabetes. However, trends and disparities in CGM use remain poorly characterized in general type 1 diabetes population. Methods: We conducted a serial cross-sectional analysis of youth and adults with type 1 diabetes using de-identified electronic health record data from the Optum Labs Data Warehouse. Type 1 diabetes status was determined using a validated algorithm. Use of CGM was ascertained by National Drug Codes from prescription order data. We examined trends in CGM use from 2008-2010 to 2020-2022, overall and by age, sex, race/ethnicity, and insurance type. Results: We included 128,821 individuals with type 1 diabetes (17% under age 18 years; 48% female; 78% non-Hispanic White). From 2008-2010 to 2020-2022, the use of CGM increased from <1% to 47% in youth and 2% to 37% in adults with type 1 diabetes (Fig A1 and A2). Uptake of CGM was similar across age and sex, but substantially lower in racial/ethnic minority patients and those with Medicaid insurance (Fig B1-E2). Conclusion: Over the past 15 years, the use of CGM has grown significantly among persons with type 1 diabetes in the US. However, racial/ethnic and socioeconomic disparities have widened in both youth and adults. There is an urgent need to expand access to care and diabetes technology to improve care in this population. Disclosure M. Fang: None. Y. Xu: None. J. Coresh: Consultant; SomaLogic, Healthy.io. S. Ballew: None. E. Selvin: None. J. Shin: None. Funding K01 DK138273-01

查看原文本刊更多论文

1444-P：2008-2022 年美国青年和成人 1 型糖尿病患者使用连续葡萄糖监测仪的趋势和差距

简介连续血糖监测（CGM）技术为 1 型糖尿病的治疗带来了革命性的变化。然而，CGM 在普通 1 型糖尿病患者中的使用趋势和差异仍不明显。方法：我们使用 Optum Labs 数据仓库中去标识化的电子健康记录数据，对 1 型糖尿病青少年和成人患者进行了连续横断面分析。使用经过验证的算法确定 1 型糖尿病状态。CGM 的使用情况是通过处方单数据中的国家药品代码确定的。我们研究了从 2008-2010 年到 2020-2022 年 CGM 的总体使用趋势，以及按年龄、性别、种族/民族和保险类型划分的使用趋势。结果：我们纳入了 128,821 名 1 型糖尿病患者（17% 年龄在 18 岁以下；48% 女性；78% 非西班牙裔白人）。从 2008-2010 年到 2020-2022 年，CGM 的使用率在青年 1 型糖尿病患者中从 <1% 增加到 47%，在成人 1 型糖尿病患者中从 2% 增加到 37%（图 A1 和 A2）。不同年龄和性别的患者对 CGM 的使用率相似，但少数种族/族裔患者和有医疗补助保险的患者对 CGM 的使用率要低得多（图 B1-E2）。结论：在过去的 15 年中，CGM 在美国 1 型糖尿病患者中的使用率大幅提高。然而，在年轻人和成年人中，种族/族裔和社会经济差距都在扩大。目前迫切需要扩大糖尿病护理和糖尿病技术的使用范围，以改善对这一人群的护理。披露 M. Fang：无。Y. Xu：无。J. Coresh：顾问；SomaLogic、Healthy.io。S. Ballew：无。E. Selvin：无。J. Shin：无。资助 K01 DK138273-01

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.